Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using topical finasteride or dutasteride with a testosterone and NPP cycle for hair loss. The planned treatment includes microneedling, minoxidil, pyrilutamide, and dutasteride applied topically.

The conversation discusses concerns about starting finasteride with low testosterone levels, with one person suggesting finasteride might increase testosterone and decrease DHT, and another advising to pay attention to thyroid-stimulating hormone (TSH) levels.

The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.

The user received hormone test results showing normal estradiol and testosterone levels, low SHBG, and normal free androgen index. They are considering starting finasteride but are concerned due to being slightly overweight.

Peppermint oil may promote hair regrowth by decreasing scalp testosterone and DHT levels. Other herbs in the Mint family, like spearmint and rosemary, might also reduce testosterone.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

Topical dutasteride may not significantly reduce hair loss and could potentially increase testosterone, leading to further hair loss. Users report side effects like mood changes, sleep issues, and severe side effects, with no significant progress in hair regrowth.

Being overweight may increase finasteride side effects due to higher aromatase activity converting testosterone to estradiol. Maintaining a healthy weight could reduce these side effects.

Trans women discuss using finasteride and dutasteride for hair loss and whether to continue after testosterone suppression. One user reduced dutasteride dosage after achieving undetectable testosterone levels.

A 20-year-old with thinning hair has low vitamin D and normal testosterone. They are prescribed oral minoxidil and vitamin D, and are questioning if finasteride is also necessary.

27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.

The conversation is about starting finasteride for hair loss, with concerns about high free testosterone and potential side effects like gynecomastia. The user plans to address vitamin deficiencies before beginning the treatment.

OP experienced side effects from finasteride and is considering using RU58841 to prevent hair loss during a testosterone cycle. They have also used minoxidil, Nizoral, alfatradiol, and fluridil successfully.

A 33-year-old man experienced diffuse thinning and hair shedding due to sleep deprivation and low testosterone. After starting hCG treatment, he noticed hair regrowth on his temples.

A user is considering Spironolactone for hair loss but is advised against it due to its effects on testosterone. Instead, they are recommended to try finasteride at 18 and consider dutasteride if needed.

The conversation discusses using aromatase inhibitors with dutasteride or finasteride for hair loss, which can prevent testosterone from turning into estrogen but may lead to increased DHT and potentially make finasteride less effective. There's concern about proper dosing and side effects like gynecomastia and emotional changes.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

A user on finasteride for 7+ months shared bloodwork results, questioning if high DHT levels and testosterone could affect cholesterol. Replies suggest consulting a doctor and question the high testosterone levels.

The conversation is about adding crushed bicalutamide or spironolactone to a topical mix with finasteride and minoxidil to suppress testosterone in hair follicles, similar to what RU58841 does. The user cannot obtain RU58841 in their country and is seeking advice on this alternative approach for hair loss treatment.

A potential treatment for hair loss that involves injecting fat into the scalp; the role of testosterone and estrogen in thinning fat tissue under the skin; research on using lard to treat androgenic alopecia, as well as PRP + ACELL/amniotic stem cell treatments; and ongoing clinical trials by doctors involved in the study.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.

The user switched from finasteride to dutasteride due to side effects and is experiencing fewer side effects with dutasteride, though some scalp itching has occurred. Blood tests show elevated testosterone and estrogen, low DHT, and normal liver and cholesterol levels, leading the user to feel confident in the long-term benefits of dutasteride for hair regrowth.

17-alpha-estradiol may work for hair loss by inhibiting 5-alpha reductase, similar to finasteride. It might lower testosterone in the scalp, reducing DHT conversion.

Cyperus rotundus oil is suggested as a natural treatment for androgenic alopecia, potentially inhibiting hair growth without affecting testosterone levels. The conversation questions its effectiveness and safety for scalp use.

The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.

An 18-year-old is dealing with early hair loss and feels unsupported. They have started oral minoxidil and are considering finasteride but are worried about side effects due to high testosterone levels.

Hair loss treatments like spironolactone often require lifelong use to maintain results. Stopping the medication can lead to increased testosterone levels and potential hair loss.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.